Selective Cardiac Neuroadrenergic Abnormalities in Hypertensive Patients with Left Ventricular Hypertrophy

Archives of Medical Research

Volumn 38, Issue 5, 2007, Pages 512-518

  Giordano, Alessandro ^a   Melina, Giovanni ^b   Calcagni, Maria Lucia ^a   Schinzari, Francesca ^a   Cirillo, Fiammetta ^a   Mettimano, Marco ^a   Cardillo, Carmine ^a   Melina, Domenico ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Essential hypertension; Left ventricular hypertrophy; Metaiodobenzylguanidine; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THALLIUM 201;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART SCINTISCANNING; HUMAN; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC TONE;

3-IODOBENZYLGUANIDINE; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; SYMPATHETIC NERVOUS SYSTEM; THALLIUM RADIOISOTOPES;

EID: 34250017450     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.01.009     Document Type: Article

References (26)

1. Hoefnagel C.A. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 21 (1994) 561-581
2. Troncone L. Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray P.C., Ell P.J., and Strauss H.W. (Eds). Nuclear Medicine in Clinical Diagnosis and Treatment, Vol. II (1994), Churchill Livingstone, Edinburgh 745-756
3. Merlet P., Caussin C., Poiseau E., Piot O., Maziere B., and Syrota A. In vivo assessment of neurotransmitter system in cardiovascular diseases. QJ Nucl Med 40 (1996) 108-120
4. 123I-MIBG radioaerosol as a marker of the pulmonary neuroadrenergic function. Eur J Nucl Med 24 (1997) 52-58
5. Laks M.M., Morady F., and Swan H.J.C. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64 (1973) 75-78
6. Ostman-Smith I. Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci (Colch) 61 (1981) 265-272
7. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha I adrenergic response. J Clin Invest 72 (1983) 732-738
8. Esler M. The sympathetic system and hypertension. Am J Hypertens 13 (2000) 99S-105S
9. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
10. Messerli F.H. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Hypertens 6 (1993) 335-336
11. van Zwieten P.A. The influence of antihypertensive drug treatment on the preventrion and regression of left ventricular hypertrophy. Cardiovasc Res 45 (2000) 82-91
12. Kuwahara T., Hamada M., and Hiwada K. Direct evidence of impared cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 39 (1998) 1486-1491
13. 123I-MIBG. J Nucl Med 40 (1999) 6-11
14. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
15. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Int J Cardiovasc Imaging 18 (2002) 539-542
16. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
17. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 55 (1977) 613-618
18. Esler M., Jennings G., and Lambert G. Noradrenaline release and pathophysiology of primary human hypertension. Am J Hypertens 2 (1989) 140S-246S
19. Mancia G., Grassi G., Giannattasio C., and Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34 (1999) 724-728
20. Julius S., Pascual A., Reilly K., and London R. Abnormalities of plasma volume in borderline hypertension. Arch Intern Med 127 (1971) 116-119
21. Carter C., McGee D., Reed D., Yano K., and Stemmermann G. Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. Am Heart J 105 (1983) 674-679
22. Esler M., Rumantir M., Wiesner G., Kaye D., Hastings J., and Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14 (2001) 304S-309S
23. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
24. Medical research council working party. MRC trial of treatment of mild hypertension: principal results. BMJ 291 (1985) 97-104
25. Yamada Y., Miyajima E., Tochikubo O., Matsukawa T., and Ishi M. Age-related changes in muscle sympathetic activity in essential hypertension. Hypertension 13 (1989) 870-877
26. Rabinovitch M.A., Rose C.P., Schwab A.J., Fitchett D.H., Honos G.N., Stewart J.A., et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 34 (1993) 589-600